Psychotherapy of depression in patients with breast cancer

Effectiveness of psychodynamic short-term psychotherapy of depression in patients with breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN96793588

Enrollment

180

Registered

2008-08-07

Start date

2007-10-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder in patients with breast cancer Mental and Behavioural Disorders Reaction to severe stress and adjustment disorders

Interventions

Because this is a multicentre study there are two study centres (University of Mainz and University of Leipzig). Each study centre inserts half of the targeted number of patients (N = 90 Mainz and N =

each session 50 minutes long, frequency one session/week for sessions 1 - 18 and one session/two weeks for sessions 19 and 20. Follow up will be 6 months after finishing SET in the intervention group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Breast cancer, curative treatment intent 2. Elevated score (greater than or equal to 8) of depression on the Hospital Anxiety and Depression Scale (HADS) and diagnosis of depression (International Classification of Diseases [ICD-10] diagnoses depressive episode [F32], recurrent depressive disorder [F33], dysthymia [F34.1], adjustment disorders [F43.21]) according to the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders - fourth edition (SCID-I-DSMIV) 3. Aged 18 - 70 years, females

Exclusion criteria

Exclusion criteria: 1. Severe medical conditions (metastases, cognitive impairments) 2. Severe psychiatric disorders (psychotic disorder, risk of self-harm, acute substance-related disorder, personality disorders except for cluster C, organic mental disorder) 3. Concurrent psychotherapeutic treatment

Design outcomes

Primary

Measure	Time frame
Remission of depression: 1. HADS: decrease of at least 2 points 2. SCID-I: no diagnosis of depressive disorder Timepoints: Screening = T0 = 0 months Baseline = T1 = 0 months End of treatment = T2 = ca. 6 months after baseline diagnsotics Follow-up = T3 = ca. 12 months after baseline diagnostics	—

Secondary

Measure	Time frame
Improvement of quality of life. Timepoints: Baseline = T1 = 0 months End of treatment = T2 = ca. 6 months after baseline diagnsotics Follow-up = T3 = ca. 12 months after baseline diagnostics	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 24, 2026